Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity, the ...